Skip to main content
Premium Trial:

Request an Annual Quote

Florida Clears Genetic Technologies' BrevaGen for Sale

NEW YORK (GenomeWeb News) – Genetic Technologies today said that its BrevaGen breast cancer risk stratification test has been cleared by Florida for sale in the state.

The Clinical Laboratory Unit of the Florida Agency for Healthcare Administration cleared the test, following similar action by California authorities in July. This leaves New York as the only state where BrevaGen has not been cleared for sale. Genetic Technologies said that it has submitted to the New York State Department of Health, Clinical Laboratory Evaluation Program to offer Out of State Clinical Laboratory services to New York residents, and its application is being reviewed.

Genetic Technologies received CLIA registration last year for its lab.

Citing statistics from the American Cancer Society, Genetic Technologies said Florida has about 15 percent of all breast cancer incidents in the US. The Australian firm's US subsidiary, Phenogen Sciences, has trained and put into place in Florida a regional business manager, and Genetic Technologies expects to start selling BrevaGen immediately in the state.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.